PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8283069

Improving NLEP performance in a low endemic area.

R Bharti·R Saini
View original source ↗Export metadata ↓

Abstract

New innovative strategies of the medical officer of an upgraded urban leprosy centre of a low endemic state (Punjab) resulted in an increase in new case detection by seventy-four percent. Indigenous patients were much more regular than immigrant patients in colonies. The number of new indigenous punjabi patients has not shown any decline in last one decade, probably because of deficiencies in the functioning of NLEP. It is suggested that improved case detection by adopting strategies used by the authors and restricting free migration of untreated and partially treated patients would help in achieving the goals of NLEP.

Explore related subjects

Drug Therapy, CombinationHumansIndiaLeprosyRetrospective StudiesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Bharti, R Saini. Improving NLEP performance in a low endemic area.. https://pubmed.ncbi.nlm.nih.gov/8283069/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosus].

According to the NIH scheme, the "evidence based medicine" standard in the treatment of severe proliferative lupus-nephritis is cyclophosphamide in combination with steroids. Undesired effects, therapy resistance, and deficient long-term effects underscore the necessity for the development of alternative therapies for the treatment of organ involvement. Mycophenolate mofetil (MMF) possesses the potential to decisively improve the therapeutic possibilities for systemic lupus erythematosus (SLE). On the basis of the available data, MMF represents an alternative to the current standard therapies for severe lupus-nephritises and shows less toxicity. MMF is also effective in patients with other manifestations refractory to conventional therapy. Questions remain unanswered on the optimal dosage and possible reduction in cases of remission. In addition, the duration of maintenance therapy is unclear. Therefore, large, prospective, randomized clinical studies in the treatment of lupus-nephritis with a sufficiently long follow-up phase are underway.

Drug Therapy, Combination↗